Adelaide, Australia, 30th June 2020 – Australian biotechnology company GPN Vaccines, which is developing a vaccine against the world’s foremost bacterial pathogen, Streptococcus pneumoniae, is pleased to announce it has raised A$7 million (USD$4.9 million) in an oversubscribed Series A2 investment round. GPN Vaccines has created...
Adelaide, Australia, 25 May 2020 – GPN Vaccines is pleased to announce Dr Ismail Kola has joined the Company’s Board of Directors. Dr Kola is a Senior Partner at Forepont Capital, a New York-based venture capital firm investing in pharmaceutical and biotechnology companies that improve healthcare outcomes....
Adelaide, Australia, 6 May 2020 – GPN Vaccines is pleased to announce Dr Gladys Monroy has joined the Company’s Scientific & Advisory Board. Dr Monroy is a world-leading intellectual property lawyer with expertise in strategic counselling and comprehensive patent portfolio management in the life sciences sector....
Adelaide, Australia, 11th April 2020 – GPN Vaccines is pleased to announce it has been awarded $1 million from the South Australian Government’s Research, Commercialisation and Startup Fund (RCSF) to support a first in human clinical trial on the Company's broad-spectrum pneumonia vaccine. Established in 2019,...
Adelaide, Australia, 7 April 2020 – GPN Vaccines is pleased to announce the appointment of Dr Paul Wabnitz as the Company's Medical Director and Mr Jim Ackland as Director, Regulatory & Quality. These two appointments will significantly strengthen the clinical development team in preparation for...
Adelaide, Australia, 18 March 2020 – GPN Vaccines is pleased to announce Ms Eve Michelle Martin has been appointed as Company Secretary and General Counsel. Ms Martin will replace Dr Tim Hirst who has resigned as Company Secretary to focus on his role as Chairman & CEO...